Cuzick J - Search Results

1

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.

Buus R, Yeo B, Brentnall AR, Klintman M, Cheang MCU, Khabra K, Sestak I, Gao Q, Cuzick J, Dowsett M. Buus R, et al. Among authors: cuzick j. Breast Cancer Res. 2018 Sep 4;20(1):103. doi: 10.1186/s13058-018-1040-9. Breast Cancer Res. 2018. PMID: 30180877 Free PMC article.

2

Adjuvant use of anastrozole in breast cancer.

Cuzick J, Buzdar A, Baum M, Bianco R, Coleman R, Constenla M, Distler W, Dowsett M, Forbes J, Guastalla JP, Houghton J, Williams N, Howell A, Locker G, MacKey J, Sainsbury R, Tobias J. Cuzick J, et al. J Clin Oncol. 2004 Apr 15;22(8):1524-6; author reply 1526-7. doi: 10.1200/JCO.2004.99.165. J Clin Oncol. 2004. PMID: 15084628 No abstract available.

3

Tamoxifen and breast density in women at increased risk of breast cancer.

Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Cuzick J, et al. J Natl Cancer Inst. 2004 Apr 21;96(8):621-8. doi: 10.1093/jnci/djh106. J Natl Cancer Inst. 2004. PMID: 15100340 Clinical Trial.

4

Early stopping of clinical trials.

Cuzick J, Howell A, Forbes J. Cuzick J, et al. Breast Cancer Res. 2005;7(5):181-3. doi: 10.1186/bcr1280. Epub 2005 Jun 21. Breast Cancer Res. 2005. PMID: 16168134 Free PMC article.

5

Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.

Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Dowsett M, et al. Among authors: cuzick j. J Clin Oncol. 2005 Oct 20;23(30):7512-7. doi: 10.1200/JCO.2005.01.4829. J Clin Oncol. 2005. PMID: 16234518 Clinical Trial.

6

Bone versus breast density.

Cuzick J. Cuzick J. Breast Cancer Res. 2006;8(3):104. doi: 10.1186/bcr1407. Epub 2006 May 2. Breast Cancer Res. 2006. PMID: 16677421 Free PMC article.

7

Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.

Buzdar AU, Guastalla JP, Nabholtz JM, Cuzick J, ATAC Trialists' Group. Buzdar AU, et al. Among authors: cuzick j. Cancer. 2006 Aug 1;107(3):472-80. doi: 10.1002/cncr.22042. Cancer. 2006. PMID: 16804925 Free article.

8

Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).

Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE; ATAC Trialists' group. Eastell R, et al. Among authors: cuzick j. J Bone Miner Res. 2006 Aug;21(8):1215-23. doi: 10.1359/jbmr.060508. J Bone Miner Res. 2006. PMID: 16869719 Free article. Clinical Trial.

9

Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.

Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J. Sestak I, et al. Among authors: cuzick j. J Clin Oncol. 2006 Aug 20;24(24):3991-6. doi: 10.1200/JCO.2005.04.3745. J Clin Oncol. 2006. PMID: 16921052

10

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.

Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A; International Breast Cancer Intervention Study I Investigators. Cuzick J, et al. J Natl Cancer Inst. 2007 Feb 21;99(4):272-82. doi: 10.1093/jnci/djk049. J Natl Cancer Inst. 2007. PMID: 17312304 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

682 results

Search Page